Ionis Pharmaceuticals Analyst Ratings
J.P. Morgan Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Raises Target Price to $55
Analysts Offer Insights on Healthcare Companies: CureVac (CVAC), Vericel (VCEL) and Twist Bioscience (TWST)
CareDx Analyst Ratings
BTIG Upgrades CareDx(CDNA.US) to Buy Rating, Announces Target Price $40
Craig-Hallum Maintains CareDx(CDNA.US) With Buy Rating, Raises Target Price to $40
Oppenheimer Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Raises Target Price to $27
Nurix Therapeutics Analyst Ratings
Navigating 11 Analyst Ratings For 10x Genomics
Analysts Offer Insights on Healthcare Companies: Insulet (PODD), Carisma Therapeutics (CARM) and Recursion Pharmaceuticals (RXRX)
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Genmab (GMAB) and Xoma (XOMA)
10x Genomics Analyst Ratings
Morgan Stanley Maintains 10x Genomics(TXG.US) With Buy Rating, Cuts Target Price to $46
Morgan Stanley Maintains Veracyte(VCYT.US) With Sell Rating, Maintains Target Price $26
Intellia Therapeutics (NTLA) Receives a Buy From J.P. Morgan
Veracyte Analyst Ratings
Analyst Issues Sell Rating for Veracyte Amidst Strong Q2 Growth but Limited Near-Term Upside
CRISPR Therapeutics Analyst Ratings
Buy Rating Affirmed for Intellia Therapeutics Following Successful Phase II Trials and Strong Cash Reserves
Truist Adjusts Price Target on CRISPR Therapeutics to $100 From $120, Maintains Buy Rating